OVIDOvid Therapeutics Inc.

Nasdaq ovidrx.com


$ 3.07 $ -0.02 (-0.65 %)    

Thursday, 09-May-2024 15:59:51 EDT
QQQ $ 441.33 $ 0.87 (0.2 %)
DIA $ 394.43 $ 3.95 (1.01 %)
SPY $ 520.56 $ 3.37 (0.65 %)
TLT $ 90.69 $ 0.50 (0.55 %)
GLD $ 216.93 $ 3.35 (1.57 %)
$ 3.05
$ 3.06
$ 0.00 x 0
$ 0.00 x 0
$ 3.02 - $ 3.08
$ 2.57 - $ 4.14
99,242
na
218.09M
$ 0.82
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-08-2024 12-31-2023 10-K
2 11-03-2023 09-30-2023 10-Q
3 08-04-2023 06-30-2023 10-Q
4 05-05-2023 03-31-2023 10-Q
5 03-13-2023 12-31-2022 10-K
6 11-08-2022 09-30-2022 10-Q
7 08-09-2022 06-30-2022 10-Q
8 05-10-2022 03-31-2022 10-Q
9 03-15-2022 12-31-2021 10-K
10 11-10-2021 09-30-2021 10-Q
11 08-16-2021 06-30-2021 10-Q
12 05-13-2021 03-31-2021 10-Q
13 03-15-2021 12-31-2020 10-K
14 11-13-2020 09-30-2020 10-Q
15 08-10-2020 06-30-2020 10-Q
16 05-07-2020 03-31-2020 10-Q
17 03-11-2020 12-31-2019 10-K
18 11-08-2019 09-30-2019 10-Q
19 08-07-2019 06-30-2019 10-Q
20 05-07-2019 03-31-2019 10-Q
21 03-07-2019 12-31-2018 10-K
22 11-08-2018 09-30-2018 10-Q
23 08-09-2018 06-30-2018 10-Q
24 05-08-2018 03-31-2018 10-Q
25 03-29-2018 12-31-2017 10-K
26 11-09-2017 09-30-2017 10-Q
27 08-10-2017 06-30-2017 10-Q
28 06-13-2017 03-31-2017 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 citigroup-maintains-neutral-on-ovid-therapeutics-lowers-price-target-to-35

Citigroup analyst Yigal Nochomovitz maintains Ovid Therapeutics (NASDAQ:OVID) with a Neutral and lowers the price target fro...

 b-riley-securities-initiates-coverage-on-ovid-therapeutics-with-buy-rating-announces-price-target-of-9

B. Riley Securities analyst Kalpit Patel initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Buy rating and announc...

 hc-wainwright--co-initiates-coverage-on-ovid-therapeutics-with-buy-rating-announces-price-target-of-9

HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Buy rating a...

 wedbush-initiates-coverage-on-ovid-therapeutics-with-outperform-rating-announces-price-target-of-8

Wedbush analyst Laura Chico initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Outperform rating and announces Pri...

 over-2m-bet-on-nextnav-check-out-these-3-penny-stocks-insiders-are-aggressively-buying

The Dow Jones index closed higher by over 400 points on Wednesday. When insiders purchase or sell shares, it indicates their co...

 ovid-therapeutics-q4-2023-gaap-eps-0220-misses-0100-estimate-sales-141562k-beat-56500k-estimate

Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.220) per share which missed the analyst consensus estimate of ...

 ovid-therapeutics-filed-us-patent-application-20240009160-	use-of-s-3-amino-4-difluoromethylenylcyclopent-1-ene-1-carboxylic-acid-in-the-treatment-of-cancer

https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20240009160

 btig-initiates-coverage-on-ovid-therapeutics-with-buy-rating-announces-price-target-of-11

BTIG analyst Thomas Shrader initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Buy rating and announces Price Targ...

 ovid-therapeutics-inc-says-may-offer-and-sell-shares-of-our-common-stock-having-an-aggregate-offering-price-of-up-to-75m-from-time-to-time

-SEC Filing

 ovid-therapeutics-inc-files-for-mixed-shelf-of-up-to-250m

- SEC Filing

 ovid-therapeutics-q3-eps-016-beats-019-estimate-sales-10900k-beat-5000k-estimate

Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0...

Core News & Articles

Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing medicines that transform the lives of...

 ovid-therapeutics-q2-eps-018-beats-020-estimate-sales-7500k-beat-5000k-estimate

Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION